Company Summary:
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Job Summary:
Tessera Therapeutics is seeking an enthusiastic and experienced scientist to fulfil the Principal Scientist/Associate Director of Proteomics role in our DMPK group. The candidate will develop, validate, and employ LC/MS based proteomics approaches to analyze biological samples and to discover biomarkers to support research, non-clinical, and clinical development programs for a variety of therapeutic indications. The ideal candidate must have excellent communication skills and be willing to work in a highly dynamic and fast-paced work environment.
Job Responsibilities
Develop, optimize, and validate LC-MS/MS methods for quantitation of proteins in various biological matrices including biofluids, tissues and cells. Design and execute proteomics experiments from sample preparation, LC-MS/MS operation to data analysis & interpretation. Build and lead a proteomics team to support gene writing platform research, non-Clinical, and clinical programs. Discover and validate potential biomarker for supporting preclinical and clinical programs. Establish, optimize, and maintain the workflow of proteomics studies. Manage external vendors to support development programs and platform work. Write proteomic reports and contribute to regulatory documents for IND/CTA filings. Provide maintenance, quality control and troubleshooting of Orbitrap mass spectrometer as well as HPLC/nano-LC systems.
Basic Qualifications:
PhD in a biological or related discipline e.g., Biology, Biochemistry, Chemistry, Biotechnology or Pharmaceutical Science with 5+ years' industry experience after postdoc. Experience in both targeted and global proteomics is required. Excellent knowledge and hands-on experience in proteomics sample preparation techniques such as immuno-protein/peptide enrichment and LC/MS based method development and data processing for protein characterization and quantification applications. Extensive experience in protein isolation and purification from cells, tissues, and biofluids. High level of proficiency in a variety of quantitative proteomics techniques -TMT, SILAC, label-free quantification approaches and peptide fragmentation methods. Proficiency of using one of Thermo Orbitrap mass spectrometers: Q Exactive series or Exploris series. Experience in using Xcalibur, Skyline, Proteome Discoverer, and BioPharma software. Excellent organizational and communication skills. Ability to conduct multiple laboratory and project tasks efficiently. Ability to work in a team-oriented environment. Experience with downstream statistical and bioinformatics analysis is a plus.
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, "FSP") do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering's internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.